发明名称 |
ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE |
摘要 |
The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis. |
申请公布号 |
US2015086567(A1) |
申请公布日期 |
2015.03.26 |
申请号 |
US201414538673 |
申请日期 |
2014.11.11 |
申请人 |
CEDARS-SINAI MEDICAL CENTER |
发明人 |
Gonsky Rebecca;Deem Richard;Targan Stephan R. |
分类号 |
C12Q1/68;C07K16/24 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of diagnosing susceptibility to an inflammatory bowel disease (IBD) subtype in an individual, comprising:
(a) obtaining a sample from the individual; (b) assaying the sample to determine the presence or absence of at least one risk genetic variant at the genetic locus of IFNG; and (c) diagnosing susceptibility to the IBD subtype based on the presence of at least one risk genetic risk variant at the genetic locus of IFNG. |
地址 |
LOS ANGELES CA US |